Valuation is grounded on a normalized 6.5x EV/EBITDA multiple applied to a sustainable $120M EBITDA (implied by 74% gross margin, moderate opex, and ongoing growth in consumables). Share count is based on the most recent reported 112M shares. Scores reflect strong recurring revenue, margin resilien…
10x Genomics (TXG) Q2 2026: ATERA Orders Surpass 40-Unit Capacity, Signaling Demand Inflection
ATERA’s unprecedented early demand and broad customer engagement marked a turning point for 10x Genomics, with order flow far exceeding current manufacturing capacity and driving a spatial market transition. Management raised full-year guidance on the back of robust consumables growth and spatial momentum, despite instrument headwinds as customers await ATERA shipments. With AI-driven biological research accelerating, 10x’s platform strategy and multiomic expansion position it at the center of next-generation discovery, but near-term execution will hinge on scaling production and navigating academic funding constraints.
Summary
- ATERA Demand Redefines Spatial Market: Orders already exceed 2026 capacity, catalyzing a spatial platform shift.
- Consumables Growth Offsets Instrument Pause: Core consumables outperformed as customers prepare for new platform adoption.
- AI and Multiomics Fuel Long-Term Tailwind: Platform differentiation and data quality anchor 10x in AI-driven research transformation.
Business Overview
10x Genomics develops and sells advanced genomics instruments and consumables that enable high-resolution single-cell and spatial biology analysis, serving academic, medical, and biopharma research markets. The company’s business model is anchored in recurring consumables revenue—from single-cell (Chromium) and spatial (Xenium, Visium, and now ATERA) platforms—while instrument sales provide initial placement and ecosystem expansion. Multiomics, the integration of multiple biological data types, is a core area of growth, with recent moves into proteomics and AI-enabled analytics.
Performance Analysis
10x Genomics delivered 3% year-over-year revenue growth (excluding non-recurring settlement revenue), as robust consumables sales offset a sharp decline in instrument placements. Consumables revenue rose 7%, led by spatial (up 16%) and single-cell (up 3%), reflecting expanding usage across major disease areas and research applications. Instrument revenue fell 47%, with both Chromium and spatial instruments declining as customers paused purchases ahead of the ATERA launch—a dynamic management had anticipated and flagged as a transition headwind.
Gross margin increased to 74%, driven by lower manufacturing costs, tariff refunds, and reduced inventory write-downs, underscoring operational discipline even as operating expenses remained flat after adjusting for litigation gains. Cash and equivalents rose to $552 million, providing strategic flexibility. Geographically, EMEA outperformed with 15% growth, while APAC declined due to prior-year pull-forwards and ongoing China volatility. Management’s guidance raise reflects confidence in ATERA’s ramp and continued consumables strength, but also embeds a cautious view on academic funding flows and macro stability.
- Spatial Transition Dynamic: Customers delayed spatial instrument purchases, anticipating ATERA, creating a temporary revenue dip but setting up for a Q4 inflection.
- Flex Apex Adoption Drives Single-Cell Volume: The Flex Apex assay, enabling scalable, distributed sample collection, is fueling larger, more ambitious studies, especially in biopharma.
- AI as a Structural Demand Tailwind: Most significant biological data generation efforts now aim to train AI models, positioning 10x’s high-quality, multiomic data as foundational for next-gen drug discovery.
Management expects the spatial transition to peak in Q3, with a significant step up in Q4 as ATERA shipments ramp and begin to meaningfully contribute to revenue, supported by normal seasonal strength across the portfolio.
Executive Commentary
"The story of the quarter was the extraordinary customer response to Atera. We're highly encouraged by the engagement across the research ecosystem and the very strong early order flow."
Serge Saxonov, CEO and Co-Founder
"As of the end of the second quarter, booked orders already greatly exceeded that full year number. That said, our shipment outlook of approximately 40 units for the year remains unchanged as we continue ramping production."
Adam Taich, Chief Financial Officer
Strategic Positioning
1. ATERA Platform Launch: Market-Making Demand
ATERA, the new spatial whole-transcriptome platform, has generated “strikingly large” early orders, with customer enthusiasm broad and deep across academia and industry. Management’s conviction is that ATERA will become the cornerstone for spatial biology, enabling previously impossible research questions and driving the next wave of market expansion.
2. Consumables Recurrence and Volume Expansion
Recurring consumables revenue underpins business resilience, with Flex Apex and multiomic panels driving larger, more complex studies. The shift toward centralized processing and distributed sample collection is increasing consumables pull-through, even as instrument placements slow during the platform transition.
3. AI Integration and Multiomic Differentiation
AI-driven biological research is now pervasive, with most large-scale projects designed to train models on single-cell and spatial data. 10x’s platforms are recognized for data quality, scale, and multiomic breadth, making them the preferred choice for both academic consortia and biopharma AI initiatives.
4. Operational Scaling and Manufacturing Readiness
The main constraint on ATERA growth is not demand but manufacturing capacity, as 10x leverages prior operational investments to scale production. Management expects to build out capacity further in 2027 and beyond, with a focus on maximizing early adopter utilization and supporting service providers to broaden access.
5. Clinical and Diagnostic Expansion Roadmap
10x continues to invest in generating clinical evidence for future diagnostic applications, with new partnerships in oncology and autoimmunity. The company’s strategy is to leverage its research dominance as a springboard into clinical markets as evidence and regulatory pathways mature.
Key Considerations
This quarter marks a pivotal inflection for 10x Genomics, with ATERA’s launch reshaping the spatial market and positioning the company as a critical enabler of AI-powered biological discovery. Investors should weigh the near-term transition volatility against the long-term platform opportunity.
Key Considerations:
- ATERA Capacity Bottleneck: Supply, not demand, limits near-term revenue recognition, with 40 units guiding the 2026 ramp and a backlog building for 2027.
- Consumables Revenue Resilience: Recurring sales from expanding assay usage and multiomics adoption underpin financial stability through platform transitions.
- AI-Driven Market Expansion: As AI becomes integral to drug discovery, 10x’s data quality and platform breadth create a structural advantage and new revenue streams.
- Academic Funding Uncertainty: Grant flows remain sluggish, with sentiment improving but actual purchasing still constrained, limiting upside from this segment in guidance.
- Competitive and Product Cycle Risks: Execution on ATERA’s roadmap, including automation and proteomics, will be critical to maintaining leadership as the spatial field evolves.
Risks
Execution risk looms around scaling ATERA production and delivering on the platform’s ambitious roadmap, especially as customer expectations and backlog grow. Academic funding delays and macro volatility could limit near-term upside, while competitive pressure in spatial and single-cell markets remains intense. Failure to convert early ATERA enthusiasm into sustained adoption or operational missteps in manufacturing could undermine the growth narrative.
Forward Outlook
For Q3 2026, 10x Genomics guided to:
- A modest sequential step down in total revenue, reflecting peak spatial transition as customers await ATERA.
- Continued consumables growth, though with some pull-forward from Q4 as projects are paused in anticipation of new platform availability.
For full-year 2026, management raised guidance to:
- $610 million to $630 million in revenue (2% to 5% growth, excluding non-recurring items).
Management emphasized:
- ATERA shipments will drive a significant Q4 revenue inflection, with the majority of the step up coming from platform placements.
- Guidance assumes no improvement in academic funding or macro conditions, so any upside there would be incremental.
Takeaways
10x Genomics is at a critical transition, with ATERA’s launch redefining customer expectations and market structure. Consumables resilience and AI adoption provide ballast, but execution on scaling and transition dynamics will dictate near-term performance.
- ATERA Demand Outstrips Supply: Early orders already exceed 2026 capacity, setting up a backlog and supporting a multi-year growth runway if manufacturing scales as planned.
- Recurring Revenue Insulates Against Transition Volatility: Consumables growth, especially in spatial and Flex Apex, offsets instrument headwinds and underpins raised guidance.
- Investors Should Track Production Ramp and Academic Funding Flows: The pace of ATERA shipments and any improvement in grant-driven demand will be key swing factors for 2027 and beyond.
Conclusion
10x Genomics delivered a strategically significant quarter, with ATERA’s launch catalyzing a shift in the spatial market and validating the company’s long-term platform vision. While near-term volatility remains, especially around instrument transitions and academic funding, the company is well positioned for secular growth as AI and multiomics reshape biological research.
Industry Read-Through
10x Genomics’ ATERA launch signals an industry-wide inflection in spatial biology, with broad and deep customer engagement accelerating the shift toward integrated, high-throughput analysis platforms. AI’s growing role in research is driving demand for high-quality, multiomic data, raising the bar for platform providers across genomics, proteomics, and bioinformatics. Competitors will need to match 10x’s pace of innovation and operational scaling to remain relevant, while instrument transitions may create temporary headwinds for peers with legacy portfolios. Academic funding constraints remain a secular risk, but the structural tailwind from AI integration and multiomic research is likely to benefit the broader life sciences tools sector.